• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

脊柱关节炎。脊柱关节炎的达标治疗——我们有计划了吗？

Spondyloarthritis. Treat-to-target in spondyloarthritis--do we have a plan?

机构信息

Division of Rheumatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.

出版信息

Nat Rev Rheumatol. 2013 Sep;9(9):507-8. doi: 10.1038/nrrheum.2013.123. Epub 2013 Aug 6.

DOI:10.1038/nrrheum.2013.123
PMID:23917954
Abstract

Clinicians now have the therapies and outcome tools to implement treat-to-target strategies aimed at achieving and maintaining adequate function and control of symptoms in spondyloarthritis and psoriatic arthritis. However, validation of surrogate markers of structural progression is a prerequisite for treat-to-target strategies aimed at improving long-term outcomes such as joint damage.

摘要

临床医生现在拥有治疗目标策略的疗法和结果工具，旨在实现和维持脊柱关节炎和银屑病关节炎的充分功能和症状控制。然而，结构进展替代标志物的验证是旨在改善长期结果（如关节损伤）的治疗目标策略的前提。

相似文献

1
Spondyloarthritis. Treat-to-target in spondyloarthritis--do we have a plan?脊柱关节炎。脊柱关节炎的达标治疗——我们有计划了吗？
Nat Rev Rheumatol. 2013 Sep;9(9):507-8. doi: 10.1038/nrrheum.2013.123. Epub 2013 Aug 6.
2
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.治疗中轴型和外周型脊柱关节炎，包括银屑病关节炎，以目标为导向：支持脊柱关节炎治疗目标推荐的系统文献检索结果。
Ann Rheum Dis. 2014 Jan;73(1):238-42. doi: 10.1136/annrheumdis-2013-203860. Epub 2013 Jun 5.
3
An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.生物制剂类改善病情抗风湿药治疗中轴型脊柱关节炎和银屑病关节炎的概述。
Best Pract Res Clin Rheumatol. 2018 Jun;32(3):453-471. doi: 10.1016/j.berh.2018.12.002. Epub 2019 Mar 21.
4
Spondyloarthritis: Is methotrexate effective in psoriatic arthritis?脊柱关节炎：甲氨蝶呤对银屑病关节炎有效吗？
Nat Rev Rheumatol. 2012 May 2;8(5):251-2. doi: 10.1038/nrrheum.2012.56.
5
[Spondyloarthritis including psoriatic arthritis].[脊柱关节炎，包括银屑病关节炎]
Dtsch Med Wochenschr. 2011 Oct;136(40):2033-6. doi: 10.1055/s-0031-1286388. Epub 2011 Sep 28.
6
First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.2002年至2011年类风湿关节炎、银屑病关节炎和轴性脊柱关节炎中生物性改善病情抗风湿药物的首次处方：来自北欧改善病情抗风湿药物登记处的数据
Ann Rheum Dis. 2014 Oct;73(10):1905-6. doi: 10.1136/annrheumdis-2014-205490. Epub 2014 Jul 2.
7
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.治疗脊柱关节炎，包括强直性脊柱炎和银屑病关节炎，以靶向治疗为目标：国际工作组的建议。
Ann Rheum Dis. 2014 Jan;73(1):6-16. doi: 10.1136/annrheumdis-2013-203419. Epub 2013 Jun 8.
8
Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies.脊柱关节炎和银屑病关节炎的治疗争议：聚焦生物制剂和靶向治疗。
Expert Rev Clin Immunol. 2024 Nov;20(11):1381-1400. doi: 10.1080/1744666X.2024.2384705. Epub 2024 Jul 29.
9
Understanding the Pathogenesis of Spondyloarthritis.了解脊柱关节炎的发病机制。
Biomolecules. 2020 Oct 20;10(10):1461. doi: 10.3390/biom10101461.
10
Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.改善病情抗风湿药（DMARD）及传统DMARD联合治疗中轴受累的脊柱关节炎和银屑病关节炎患者
J Rheumatol Suppl. 2015 Nov;93:65-9. doi: 10.3899/jrheum.150640.

引用本文的文献

1
Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies.早期、进展期和迟发型轴性脊柱关节炎的治疗方法以及靶向治疗策略的必要性。
Curr Rheumatol Rep. 2017 Feb;19(2):8. doi: 10.1007/s11926-017-0633-0.
2
IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients.在强直性脊柱炎患者中，IL-23/Th17轴不受肿瘤坏死因子阻断剂的影响。
Arthritis Res Ther. 2016 Feb 24;18:52. doi: 10.1186/s13075-016-0949-6.
3
Author's reply to Wendling and Prati: "treat-to-target in spondyloarthritis: implications for clinical trial designs".

本文引用的文献

1
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.治疗脊柱关节炎，包括强直性脊柱炎和银屑病关节炎，以靶向治疗为目标：国际工作组的建议。
Ann Rheum Dis. 2014 Jan;73(1):6-16. doi: 10.1136/annrheumdis-2013-203419. Epub 2013 Jun 8.
2
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.治疗中轴型和外周型脊柱关节炎，包括银屑病关节炎，以目标为导向：支持脊柱关节炎治疗目标推荐的系统文献检索结果。
Ann Rheum Dis. 2014 Jan;73(1):238-42. doi: 10.1136/annrheumdis-2013-203860. Epub 2013 Jun 5.
3
作者对温德林和普拉蒂的回复：“脊柱关节炎的治疗达标：对临床试验设计的影响”
Drugs. 2014 Sep;74(14):1717-8. doi: 10.1007/s40265-014-0289-2.
4
Comment on "treat-to-target in spondyloarthritis: implications for clinical trial designs".关于“脊柱关节炎达标治疗：对临床试验设计的启示”的评论
Drugs. 2014 Sep;74(14):1715-6. doi: 10.1007/s40265-014-0288-3.
Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification.
抑制炎症和对强直性脊柱炎新骨形成的影响：疾病修饰治疗机会窗口的证据。
Ann Rheum Dis. 2013 Jan;72(1):23-8. doi: 10.1136/annrheumdis-2011-200859. Epub 2012 May 5.
4
Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?非放射性轴性脊柱关节炎患者与强直性脊柱炎患者有何不同？
Arthritis Care Res (Hoboken). 2012 Sep;64(9):1415-22. doi: 10.1002/acr.21688.
5
Ten years' experience with needle biopsy in the early diagnosis of sacroiliitis.针吸活检在骶髂关节炎早期诊断中的十年经验
Arthritis Rheum. 2012 May;64(5):1399-406. doi: 10.1002/art.33453.
6
Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study.治疗目标为基质金属蛋白酶 3 正常化与疾病活动评分低于 2.6 联合使用，在类风湿关节炎患者中的效果优于单独使用：T-4 研究。
Ann Rheum Dis. 2012 Apr;71(4):534-40. doi: 10.1136/annrheumdis-2011-200108. Epub 2011 Oct 21.
7
Treating rheumatoid arthritis to target: recommendations of an international task force.靶向治疗类风湿关节炎：国际工作组的建议。
Ann Rheum Dis. 2010 Apr;69(4):631-7. doi: 10.1136/ard.2009.123919. Epub 2010 Mar 9.
8
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.评估使用阿达木单抗治疗长达2年的强直性脊柱炎患者脊柱的影像学进展情况。
Arthritis Res Ther. 2009;11(4):R127. doi: 10.1186/ar2794. Epub 2009 Aug 24.
9
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design.关于验证反映类风湿关节炎、银屑病关节炎和强直性脊柱炎损伤终点的可溶性生物标志物的证据水平模式的提议及研究设计建议。
J Rheumatol. 2009 Aug;36(8):1792-9. doi: 10.3899/jrheum090347.
10
Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.阿达木单抗可显著减轻强直性脊柱炎患者的脊柱和骶髂关节炎症：一项多中心、随机、双盲、安慰剂对照研究。
Arthritis Rheum. 2007 Dec;56(12):4005-14. doi: 10.1002/art.23044.